TP53 and cancer: Accordingly, this study showed that silencing of AURKA in p53-knockdown cancer cells sensitized the A549 cancer cells to gefitinib, which also proved the inhibitory action of p53 in decreasing the ability of AURKA in conferring resistance to gefitinib.